Replies to post #22140 on Pluristem Therapeutics Inc (PSTI)

[Mikems]

Private Reply (no one allowed to read this except co-spondent) -- such a rosy prognostication about the stem cell industry all depends on if new technologies better than stem cell cures will arrive, and if other current methods prove more effective. Predictions of market strength are notoriously poor (witness the ridiculous pos-pps predictions for PSTI) in the past year and before. What is good for the company is not necessarily good for stakeholders as they are constantly ripped off by dilution, false promises, bad results, twisted lies, prevaricating executives, greedy boards, poorly quantified results, specious alliances, PR flack nonsense, greedy tactics, bad strategies, over expenditures, ridiculous salaries, loss of vital employees, bad equipment, better competitors, unsafe conditions, unsanitary practices, fatal experiments, bad news, crummy goals, and questionable ideas.

[Auto1]

Unfortunately, unless stem/gene therapy costs less than current therapy + population control, we'll need a see them approved.

Can't afford people living longer and more expensive treatments sorry.